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 The Janus effect: 
two faces of aldosterone 
 Andrew S.  Brem 1 
 Inhibition of the nitric oxide pathway by  N    -nitro- L -arginine methyl 
ester ( L -NAME) is well known to produce hypertension and proteinuria, 
but the mechanisms are less straightforward. Prolonged administration 
of mineralocorticoids mimics the pathological findings produced by 
 L -NAME. Ikeda and colleagues provide a clue to the mechanism by 
showing that exposure to  L -NAME increases plasma aldosterone 50-fold, and 
that spironolactone markedly attenuates the renal changes. Thus, chronic 
 L -NAME exposure may turn out to be a model of ineralocorticoid excess. 
 Kidney International (2009)  75, 137 – 139.  doi: 10.1038/ki.2008.567 
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 In this issue of  Kidney International , Ikeda and 
colleagues1 present a series of experiments 
conducted in a previously well-described rat 
model of renal injury. With the use of an 
inhibitor of nitric oxide production,  N    -nitro-
 l -arginine methyl ester ( l -NAME), rats 
develop hypertension with proteinuria and 
evidence of renal ( brosis over a period of 12 
weeks. The authors present evidence that 
aldosterone mediates some of the renal injury 
in this model in addition to angiotensin II, a 
( nding consistent with the literature. 2 – 4 Treat-
ment with  l -NAME results not only in the 
development of hypertension and signs of 
renal fibrosis but in a more than 50-fold 
increase in plasma aldosterone. Blocking 
aldosterone action with spironolactone atten-
uates the pathological ( ndings, largely inde-
pendently of any e7 ect on blood pressure or 
dietary salt intake. * e contribution of Ikeda 
 et al. 1 lies not in producing another hyperten-
sion – renal injury model but in providing new 
clues to the hormones and pathways govern-
ing renal injury and ( brosis. 
 Ikeda and colleagues 1 show more than 
that aldosterone antagonists attenuate 
renal damage brought on by  l -NAME; 
their ( ndings support a physiological and 
probably important connection between 
nitric oxide metabolism and the genera-
tion of aldosterone. Others have previ-
ously suggested that nitric oxide acts to 
suppress aldosterone secretion directly by 
reducing steroidogenesis in zona glo-
merulosa cells and by downregulating 
angiotensin I receptors, both e7 ects inde-
pendent of guanylyl cyclase. 5 – 8 Using 
 l -NAME to block nitric oxide production 
leads to a profound increase in plasma 
aldosterone levels in the model of Ikeda 
 et al. 1 and makes one wonder whether the 
e7 ects observed are as much the result of 
prolonged mineralocorticoid excess as the 
result of nitric oxide inhibition. 
 Aldosterone has always fascinated stu-
dents of renal physiology, and the hor-
mone has an established role as one of the 
guardians of the composition of the body 
K uids, or Claude Bernard ’ s  milieu int é rieur . 
Early experiments using the toad urinary 
bladder and, later, mammalian renal col-
lecting duct cells clearly showed that 
aldosterone induced transepithelial 
sodium reabsorption. 9 * e sodium trans-
port required a speci( c receptor, which, 
when bound to the hormone, translocated 
to the cell nucleus and eventually led to 
the generation of new proteins. Seminal 
studies later followed that described aldos-
terone ’ s role in renal potassium and hydro-
gen ion secretion. Still later, syndromes of 
mineralocorticoid excess appeared in the 
clinical literature and proved the point that 
too much of a good thing could produce 
electrolyte disturbances and hypertension. 
 Early on, investigators described a curi-
ous paradox regarding aldosterone and its 
actions on the kidney. * e e7 ect of aldo-
sterone on sodium transmembrane trans-
port was easy to demonstrate in cell 
membrane preparations such as the toad 
bladder and isolated perfused renal col-
lecting ducts, yet aldosterone ’ s inK uence 
on renal sodium reabsorption in adrenally 
intact animals could not be reliably 
reproduced. 10 However, animals adrena-
lectomized before treatment with physio-
logical doses of aldosterone clearly showed 
the expected sodium reabsorptive response 
to the hormone. * is was the ( rst evidence 
that aldosterone itself was physiologically 
tightly regulated by naturally occurring 
endogenously generated factors likely 
emanating from the adrenal gland. 
 Uete and Venning first described 
candidate adrenal steroids that might 
interfere with the renal antinatriuretic 
actions of mineralocorticoids. 11 Adminis-
tration of cortisol or its 11-dehydro 
meta-bolite cortisone attenuated the anti -
natriuretic response to both deoxycorti-
costerone acetate and aldosterone in the 
adrenalectomized rat model. * is blunting 
e7 ect of cortisol and cortisone was dose 
dependent. Later, Alberti and Sharp 
expanded prior observations and provided 
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a mechanism by demonstrating that corti-
sone functioned as an aldosterone antago-
nist. 12 Cortisone had no direct e7 ect on 
sodium transport by itself, but it was able 
to displace aldosterone from its receptor. 
 Our laboratories reexamined the Alberti 
and Sharp experiment, ( rst using the toad 
urinary bladder as a model of the mam-
malian collecting duct. 13 * e toad bladder 
contains mineralocorticoid receptors and 
an NAD-dependent unidirectional form 
of 11  -hydroxysteroid dehydrogenase 
(11  -HSD). Toad bladders exposed to 11-
dehydrocorticosterone and then stimu-
lated with aldosterone exhibited a 
markedly suppressed response in tran-
sepithelial sodium transport compared 
with controls stimulated with aldosterone 
alone. A similar pattern was seen when 
bladders were exposed to corticosterone 
and then stimulated with aldosterone. 
Both corticosterone and 11-dehydrocor-
ticosterone also suppressed aldosterone-
induced renal sodium retention in the 
adrenalectomized rat model. 14 Lastly, in 
studies performed with ME Oblin, we have 
shown that 11-dehydrocorticosterone alone 
does not directly activate mineralocorticoid 
receptors, but it is able to blunt aldosterone 
activation of these same receptors. 15 As an 
aside, 11-dehydrocorticosterone has no 
e7 ect on dexamethasone binding to gluco-
corticoid receptors. Odermatt and col-
leagues extended these findings using 
transfected HEK-293 cells by demonstrat-
ing  that both 11-dehydrocorticosterone 
and cortisone in concentrations as low as 
50  n M block aldosterone (10  n M ) induced 
mineralocorticoid receptor activation. 16 
 Aldosterone ’ s second face, as a 
pro( brotic factor, is a more recent concept 
( Figure 1 ). First reports focused on 
aldosterone promoting fibrotic changes 
in the heart and contributing to heart 
failure. 17 Later, aldosterone as a ( brotic fac-
tor was implicated in the response to injury 
in various models of kidney injury, in addi-
tion to elements of the renin – angiotensin 
system. Investigators are now beginning to 
explore all the various pathways, where 
mineralocorticoids participate in the injury 
cascade. * at aldosterone may be part of 
the ( brotic response to injury is interesting 
enough but begs the question: could excess 
aldosterone exposure itself cause injury? 
 Aldosterone functions as a pro( brotic 
agent through a multitude of pathways 
well summarized elsewhere. Major organ 
targets for aldosterone-induced ( brosis, 
including the heart, vascular tissue, and 
the kidney, express mineralocorticoid 
receptors; cells and tissues devoid of min-
eralocorticoid receptors are likely immune 
to the ( brotic e7 ects of the hormone. As 
with electrolyte transport, aldosterone 
activation of serum glucocorticoid kinase 
(SGK) appears to be part of the initial 
phase of the pro( brotic process. Fibrosis 
involves a response to inflammation 
followed by activation of certain growth 
factors leading to ( broblast growth and 
net matrix production. Aldosterone seems 
to be active in all phases of this cascade; 18 
the hormone can stimulate reactive oxygen 
species, induce transforming growth factor-
  and connective tissue growth factor, and 
both increase the synthesis of extracellular 
matrix and impair matrix breakdown. 
 * e previously mentioned tight regula-
tion of aldosterone-stimulated electrolyte 
transport may also limit the pathophysi-
ological pro( brotic e7 ects of the miner-
alocorticoid. In preliminary studies, we 
have observed that cultured mouse renal 
inner medullary collecting duct cells, 
which contain mineralocorticoid recep-
tors, increase collagen production aO er 
being exposed to 10  n M aldosterone for a 
minimum of 48  h. Immortalized rat renal 
proximal tubular cells (IRPTCs) do not 
produce more collagen following 
prolonged aldosterone exposure, and 
IRPTCs do not contain mineralocorticoid 
receptors. Both 1   M spironolactone and 
1   M 11-dehydrocorticosterone e7 ectively 
prevent this increase in collagen genera-
tion. Given their suppressive effects 
on aldosterone-induced electrolyte trans-
port and now on collagen production, the 
11-keto glucocorticoid metabolites gener-
ated by renal 11  -hydroxysteroid dehy-
drogenase may function as naturally 
occurring endogenously produced 
spironolactones. 
 From our own experiments and now 
from those of Ikeda and colleagues, 1 it is 
clear that aldosterone-induced ( brotic 
changes develop over time. Acute miner-
alocorticoid secretion and action satisfy 
the needs for sodium conservation and 
potassium secretion; only prolonged 
and / or unregulated mineralocorticoid 
exposure produces ( brotic changes in 
responsive tissues. One could conclude 
from Ikeda  et al. 1 that the nitric oxide sys-
tem also plays a vital role regulating the 
many enigmatic aldosterone-activated 
pathways. 
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 Figure 1 | Two faces of aldosterone. In Roman mythology, Janus was the god of the gates or doorways 
to the home. His simultaneous gaze in two directions signified a look toward the beginning and end or 
a view at opposites. Aldosterone has an acute or semi-acute (minutes to hours) physiological function to 
regulate the composition of body fluids. Prolonged or excess exposure to the mineralocorticoid (days, 
weeks, months) produces a pathological state leading to organ fibrosis and hypertension.
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 Improving clinical trial design for 
inquiries into the mechanisms of 
cyst growth in ADPKD 
 Arlene B.  Chapman 1 
 Accurate and reliable estimates of kidney and cyst volume, the hallmark 
of disease progression in ADPKD are now available. These powerful and 
exciting tools make it possible to consider both short and long term 
randomized clinical trials in ADPKD at various stages of disease. 
Highlights of the work by Kistler and colleagues are now provided. 
 Kidney International (2009)  75, 139 – 141.  doi: 10.1038/ki.2008.596 
see original article on page 235
 
Accuracy, precision, and reliability of 
renal and cyst volume measures in 
human ADPKD
 
 Estimates of total renal and cyst volume 
based on magnetic resonance (MR) without 
gadolinium demonstrate high accuracy, 
precision, and reliability throughout a broad 
range of renal volumes in autosomal domi-
nant polycystic kidney disease (ADPKD). 
Kistler and colleagues 1 (this issue) present 
a meticulous and elegantly executed study 
of MR-based renal and cyst volume esti-
mates over time in human ADPKD. Manual 
measurements with trained readers dem-
onstrated >0.99 concordance coeA  cients 
for inter- and intrareader variability for total 
renal volume and slightly less (0.944) for 
total cyst volume. * ese ( ndings are similar 
to those of the Consortium for Radiologic 
Imaging Studies in Polycystic Kidney Dis-
ease (CRISP) study 2 (inter-reader variability 
2.1 % and intrareader variability 2.4 % for 
renal volume), in which gadolinium was 
used. High accuracy, precision, and reliabil-
ity without gadolinium enhancement allow 
for the bene( t of reduced cost of imaging 
and remove the potential risk of developing 
nephrogenic systemic ( brosis. 
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 Renal volume measurements in the 
study by Kistler  et al. 1 were completed 
with the use of manual segmentation by 
trained personnel supported with soO -
ware. * e investigators acknowledge that 
manual segmentation requires signi( cant 
effort and is therefore restricted from 
widespread use. Manual segmentation 
precludes clinical implementation for 
patients with ADPKD, and a high priority 
to develop sophisticated image analysis 
software to support more automated, 
accurate and reliable renal and cyst vol-
ume measurement is needed in ADPKD. 
Development of such technology would 
allow clinicians to focus on patients at 
high risk for progression to renal failure 
and provide valuable predictive informa-
tion to their patients. 
 Cyst volume measurements in this study 
were performed using stereological meth-
ods in T2-weighted images, similar to the 
methods used for renal volume estimates 
in the CRISP study. 2 Intra- and interob-
server variability was similar to that found 
in CRISP, without the use of gadolinium. 
However, estimations of noncystic 
parenchyma without gadolinium are not 
feasible, and this may be an important 
consideration in the evaluation of disease 
progression in ADPKD. 3 In addition, esti-
mates of renal function, using contrast-
enhanced MR imaging, a novel functional 
application of renal MR imaging, 4 are also 
not possible in this setting. 
